



Press Release



MEDTECH FISCAL 2015 REVENUE INCREASES 130% TO \$7.9 M

Montpellier, France, July 7, 2015 – MEDTECH (Euronext, FR0010892950 – ROSA), a company specialized in designing, developing and marketing innovative surgical assistance robots, announced revenue results for its fiscal fourth quarter and full year ended June 30, 2015. For fiscal year 2015, the Company reported a 130% increase in revenue to \$7.9 million.

<i>In thousands of Dollars</i>	2013/2014	2014/2015
Q4 revenue (April 1 - June 30)	1 589	3 766
Annual revenue (July 1 - June 30)	3 435	7 893

As of June 30, 2015, Medtech had a total fleet of 48 ROSA™ robots worldwide, including 21 in North America, 15 in Europe and 12 in other parts of the world, in line with its market development plans.

During the fiscal year ended June 30, 2015, Medtech sold 20 ROSA™ robots throughout the world, including 13 in the United States.

In the fiscal fourth quarter (April 1 - June 30, 2015), Medtech sold 10 ROSA™ robots (including 5 in the United States and also the first ROSA™ Spine in Europe), recording a revenue of \$3.8 million, up 137% compared with the same period in the previous financial year.

“We are very pleased with this excellent commercial performance. Sales of ROSA™ robots continued to increase significantly from quarter to quarter throughout fiscal 2015 as we began to benefit from our investments in expanding our global sales and marketing infrastructure and regulatory clearances. The Company is successfully executing on its commercial development strategy and is well positioned for continued long-term growth, particularly with the recent launch of ROSA™ Spine in Europe and the pending U.S. regulatory clearance,” said Bertin Nahum, President and Founder of Medtech.

About MEDTECH

Founded in 2002 by Bertin NAHUM and based near Montpellier, MEDTECH is a European specialist in the design, development and marketing of innovative robotic appliances to assist surgeons during their medico-surgical interventions, thus contributing to the implementation of safer, more efficient, less-invasive treatment.

In 2007, MEDTECH developed ROSA™, an innovative technological device devoted to brain surgery procedures. ROSA™ has been approved in Europe, the United States and Canada.

In 2013 Medtech received the « European Company of the Year Award » in the “robotic neurosurgery” category from Frost & Sullivan.

In July 2014, MEDTECH obtained the CE marking for its new product ROSA™ Spine, a robotic- assistive device for minimally invasive surgery of the spine.

In October 2014, MEDTECH won the « Révélation » prize in the Mediterranean Deloitte Technology Fast 50 Awards.

CONTACT MEDTECH

Christophe Sibillin
Chief Financial Officer
Tel : +33 (0)4 67 10 77 40

INVESTORS

Corinne Puissant
Tel : +33 (0)1 53 67 36 77
cpuissant@actus.fr

PRESS

Alexandra Prisa (EU)
Tel. : +33(0)1 53 67 36 90
aprisa@actus.fr

Melanie Sollid-Penton (US)
Tel : +1 646-536-7023
msollid@theruthgroup.com